The objective was to define the characteristics of a real-world patient population treated with transcatheter aortic valve implantation (TAVI), regardless of technology or access route, and to evaluate their clinical outcome over the mid to long term. Journal of the American College of Cardiology Vol. 58, No. 20, 2011. Copyright © 2011 by the American College of Cardiology Foundation ISSN 0735-1097. Published by Elsevier Inc.
Objectives: We assessed the impact of vessel size on outcomes of stenting with biolimus-eluting degradable polymer stent (BES) and sirolimus-eluting permanent polymer stent (SES) within a randomized multicenter trial (LEADERS).
Background: The eff ectiveness of durable polymer drug-eluting stents comes at the expense of delayed arterial healing and subsequent late adverse events such as stent thrombosis (ST). We report the 4 year follow-up of an assessment of biodegradable polymer-based drug-eluting stents, which aim to improve safety by avoiding the persistent infl ammatory stimulus of durable polymers
AIM: To study a cohort of consecutive patients undergoing transcatheter aortic valve implantation (TAVI) and compare the outcomes of atrial fibrillation (AF) patients vs patients in sinus rhythm (SR). World J Cardiol. January 26, 2012. Volume 4. Copyright © 2012 Baishideng. All rights reserved.
Our aim was to examine the relationship of arterial stiffness to measures of atherosclerosis, arterial calcification, and bone mineral density (BMD); the heritability of these measures; and the degree to which they are explained by common genetic influences. Journal of the American College of Cardiology. Vol. 57, No. 13, 2011. Copyright © 2011 by the American College of Cardiology Foundation. Published by Elsevier Inc. ISSN 0735-1097.
JACC: CARDIOVASCULAR IMAGING VOL. 4, NO. 3, 2011. Copyright © 2011 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN: 1936-878X. PUBLISHED BY ELSEVIER INC .
Transcatheter aortic valve replacement is now a viable option in the treatment of high-risk severe symptomatic aortic stenosis. This review describes the current data with this technology and also the potential for the future role of the technology, including potential ways to yet further improve the short- and longer-term results. JACC: CARDIOVASCULAR INTERVENTIONS VOL. 3, NO. 11, 2010. Copyright © 2010 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798. PUBLISHED BY ELSEVIER INC.
Background: A novel stent platform eluting biolimus, a sirolimus analogue, from a biodegradable polymer showed promising results in preliminary studies. We compared the safety and effi cacy of a biolimus-eluting stent (with biodegradable polymer) with a sirolimus-eluting stent (with durable polymer).
The purpose of this study was to compare the safety and efficacy of the Xience V (Abbott Vascular, Santa Clara, California) everolimus-eluting stent (EES) with the Taxus Liberté (Boston Scientific, Natick, Massachusetts) paclitaxel-eluting stent (PES) at 2-year follow-up. Journal of the American College of Cardiology. Vol. 58, No. 1, 2011. Copyright © 2011 by the American College of Cardiology Foundation. Published by Elsevier Inc. ISSN 0735-1097.
Patent foramen ovale is found in 24% of healthy adults and 38% of patients with cryptogenic stroke. This ratio and case reports indicate that patent foramen ovale and stroke are associated, probably because of paradoxical embolism. In healthy people with patent foramen ovale, embolic events are not more frequent than in controls, and therefore no primary prevention is needed. However, once ischaemic events occur, the risk of recurrence is substantial and prevention becomes an issue. Acetylsalicylic acid and warfarin reduce this risk to the same level as in patients without patent foramen ovale. Patent foramen ovale with a coinciding atrial septal aneurysm, spontaneous or large right-to-left shunt, or multiple ischaemic events potentiates the risk of recurrence. Transcatheter device closure has therefore become an intriguing addition to medical treatment, but its therapeutic value still needs to be confirmed by randomised-controlled trials. Copyright 2010 The Authors. Journal compilation. Copyright 2010 World Stroke Organization International Journal of Stroke Vol 5, April 2010, 92–102
The authors sought to define the impact of paclitaxel-coated balloon angioplasty for treatment of drug-eluting stent restenosis compared with uncoated balloon angioplasty alone. Journal of the American College of Cardiology Vol. 59, No. 15, 2012 © 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc.
Atherosclerosis is a systemic disease, which can have varied clinical presentation with involvement of multiple vascular beds. It is common to come across patients with concomitant coronary artery disease (CAD) and peripheral arterial disease (PAD), in whom panvascular revascularization is required. As they are high-risk patients with poor clinical outcome, their management requires a comprehensive multi-specialty approach. Following improvement in technical skills and hardware for percutaneous interventions in recent years, more complex lesions with adverse clinical situations can undergo intervention by a cardiologist/vascular interventionist. We hereby report a case with CAD and PAD, who underwent successful complex coronary and multiple peripheral interventions for his symptomatic disease. World J Cardiol 2012 February 26; 4(2): 48-53. Copyright © 2012 Baishideng. All rights reserved.
Pseudoaneurysm of the ascending aorta is a rare, but potentially dangerous condition. The high morbidity and mortality rate associated with its surgical management has led to the development of transcatheter approaches. We report a case of percutaneous closure of an ascending aortic pseudoaneurysm using an Amplatzer mVSD occluder device complicated by device embolization at day 27 and we review the literature of Amplatzer devices in this off-label use. Copyright 2011 Wiley Periodicals, Inc. Catheterization and Cardiovascular Interventions 79:334–338 (2012)
The purpose of this study was to investigate the efficacy and safety of glycoprotein IIb/IIIa inhibitors (GPIs) during elective percutaneous coronary intervention (PCI). Journal of the American College of Cardiology. Vol. 57, No. 10, 2011. Copyright © 2011 by the American College of Cardiology Foundation. Published by Elsevier Inc. ISSN 0735-1097.
Context: Despite dual antiplatelet therapy, stent thrombosis remains a devastating and unpredictable complication of percutaneous coronary intervention (PCI). Objective: To perform a sequential analysis of clinical and genetic factors associated with definite early stent thrombosis. Copyright ©2011 American Medical Association. All rights reserved. JAMA, October 26, 2011—Vol 306, No. 16
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos